ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Genentech will pay $75 million to license RLY-1971, Relay Therapeutics’ SHP2 inhibitor, which is in a Phase 1 trial to treat solid tumors. The deal gives Genentech access to a promising partner for its experimental inhibitor of KRAS G12C, a notoriously difficult target for cancer drugs. SHP2 helps KRAS cycle between its “on” and “off” states, and researchers think dampening its effects could increase the efficacy of KRAS inhibitors, which bind to the protein’s “off” state.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X